Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab before-and-after study in rheumatoid arthritis
IRCT20211005052683N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Reactive oxygen species, Mitochondrial membrane potential and 1 more. Started Nov 2021; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on IRCT20211005052683N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211005052683N1.